GlassScriptPhysician profile
Mark C Maiocco
NPI 1891703997
$8,536.69
in general payments reported to CMS, 2019-2025
36 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.09 · 2020: $512 · 2021: $1,466 · 2022: $1,919 · 2023: $1,782 · 2024: $1,489 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,626.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,304.56 | 2020-2025 | Farxiga, Breztri |
| Abbvie INC. | $965.17 | 2020-2025 | |
| Pfizer INC. | $957.82 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $853.38 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $676.48 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $566.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $404.60 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $398.25 | 2021-2022 | |
| Mylan Specialty L.P. | $283.91 | 2020-2024 | Yupelri |
| Sumitomo Pharma America, INC. | $261.88 | 2023-2025 | Gemtesa |
| Amgen INC. | $243.30 | 2021-2025 | Otezla, Repatha, Prolia |
| Esperion Therapeutics, INC. | $142.35 | 2020-2022 | |
| Daiichi Sankyo INC. | $129.63 | 2021-2025 | Injectafer |
| Lilly USA, LLC | $127.41 | 2021-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $120.46 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $101.52 | 2023-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $98.22 | 2021-2022 | |
| Abbott Laboratories | $98.06 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $90.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $86.20 | 2024-2025 | Gvoke Hypopen |
| Insmed, INC. | $85.01 | 2025 | Arikayce, Brinsupri |
| E.R. Squibb & Sons, L.L.C. | $84.85 | 2021-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $72.98 | 2022-2025 | Livalo, Zoryve, Seglentis |
| Harmony Biosciences LLC | $69.57 | 2021-2023 | Wakix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.39 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $34.62 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $32.82 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $29.72 | 2022 | |
| Biogen, INC. | $27.65 | 2024 | Leqembi |
| Viatris Specialty LLC | $22.28 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $19.24 | 2022 | |
| Dexcom, INC. | $18.69 | 2023 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $18.43 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.16 | 2021 | |
| Allergan, INC. | $14.09 | 2019 | |
| Seqirus USA INC | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Maiocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.